1[1]Chen S,Akbar SM,Tanimoto K,et al.Absence of CD83-T positive mature and activated dendriticcells at cancer nodules from patients with hepatocellular carcinoma:relevance to hepatocarcinogenesis.Cancer Lett,2000,148 (1):49.
2[2]Rissoan MC,Soumelis V,Kadowaki N,et al.Reciprocal control of T helper cell differentiation.Science,1999,283 (5405):1 183.
3[3]Ninomiya T,Akbar SM,Masumoto T,et al.Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma.J Hepatol,1999,31(20):323.
4[4]Santo H,Tsujiani S,Ikeguchi M,et al.Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue.Br J Cancer,1998,78:1 573.
5[5]Grohaman U,Bianchi R,Ayroldi E,et al.A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo,but IL-12 can prevent of revent the anergic state.J Immunol,1997,158(8):3 593.
7[7]Butterfield HL,Koh A,Meng W,et al.Generation of human T-cell response to an HLA-A2.1-restricted peptide derived from alpha-fetoprotein.Cancer Res,1999,59(13):3 134.
8[8]Morse MA,Deng Y,Coleman D,et al.A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)pulsed,autologos human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.Clin Cancer Res,1999,5(6):1 331.
9[9]Nestle FO,Alijagic S,Gilliet M,et al.Vaccination of melanoma patients with peptide-pulsed dendrtic cells.Nat Med,1998,4 (3):328.
10[10]Shimizu K,Fields RC,Giedlin M,et al.Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cellbased tumor vaccines.Proc Natl Acad Sci USA,1999,96 (5):2268.
